Clinical Trial Update: Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine [Phase 2]

View source ↗

Summary

Phase 2 extension study assessing antibody persistence, safety, tolerability, and immunogenicity of booster doses of Novartis rMenB±OMV NZ vaccine in children p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• rMenB±OMV NZ vaccine (meningococcal group B vaccine (rMenB±OMV NZ))

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-05-06